Navigation Links
Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference

FRANKLIN, Mass., Sept. 9 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has rescheduled the Company's presentation at the Rodman & Renshaw 2009 Annual Global Investment Conference. Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will now present on Thursday, September 10, 2009 at 11:15am ET. The presentation will occur live and will be held at The New York Palace Hotel in New York, NY.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer

SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary, Helsinn Therapeutics (U.S.) Inc.
2. Cell Therapeutics, Inc.s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
3. Reportlinker Adds Autoimmune Disease Therapeutics Report
4. Reportlinker Adds Lung Cancer Therapeutics Report
5. Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report
6. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
7. Reportlinker Adds Dermatological Therapeutics: Global Markets Report
8. Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference
9. Cornerstone Therapeutics to Present at Two Upcoming Investor Conferences
10. Selexis and NKT Therapeutics Enter Into Research Services Agreement
11. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
Post Your Comments:
(Date:11/26/2015)... ... 26, 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk ... system efficiency and reliability. , The new Q-Suite 6 platform is based on the ... locking itself into a specific piece of software for many key components of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of the ... stellar workplace culture with the company’s Cincinnati office being named a finalist among ... was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati Best ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health Partners, ... new Wimbledon Athletics Facebook page to educate the public, parents and ... abnormalities. About 2,000 people under the age of 25 die from sudden cardiac ...
(Date:11/25/2015)... ... ... Beddit® has launched a new Android app for use with ... more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes it ... a proprietary algorithm. Beddit analyzes the data to provide an easy to understand scientific ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the German Drugs ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
Breaking Medicine Technology: